CoChat

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Open access
Liu, Qiyuan Keith · 2024 · Frontiers in Endocrinology

The DOI matches its Crossref record; 275 of the 279 references it cites were found in a registry or an index.

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate the downstream signaling in various tissues and organs. Both GIP and GLP-1 play roles in regulating food intake by stimulating neurons in the brain’s satiety center. They also stimulate insulin secretion in pancreatic β-cells, but their effects on glucagon production in pancreatic α-cells differ, with GIP having a glucagonotropic effect during hypoglycemia and GLP-1 exhibiting glucagonostatic effect during hyperglycemia. Additionally, GIP directly stimulates lipogenesis, while GLP-1 indirectly promotes lipolysis, collectively maintaining healthy adipocytes, reducing ectopic fat distribution, and increasing the production and secretion of adiponectin from adipocytes. Together, these two incretins contribute to metabolic homeostasis, preventing both hyperglycemia and hypoglycemia, mitigating dyslipidemia, and reducing the risk of cardiovascular diseases in individuals with type 2 diabetes and obesity. Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases. Elucidating the underlying cellular and molecular mechanisms could potentially usher in the development of new generations of incretin mimetics with enhanced efficacy and fewer adverse effects. The treatment guidelines are evolving based on clinical trial outcomes, shaping the management of metabolic and cardiovascular diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2024.1431292

Cites

275 of 275 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Physiological and Pharmacological Effects of GIP, GLP-1 and Their Receptor Agonists. (A) GIP and GLP-1 secretion. Enteroendocrine K cells in the upper gastrointestinal tract (duodenum and jejunum) and L cells in the distal gut (ileum and colon) produce and secret GIP and GLP-1, respectively, into the circulation. GIP peptide and the downstream signaling pathways are depicted in blue, while GLP-1 peptide and the downstream signaling pathways are represented in red. The signaling pathways regulated by both GIP and GLP-1 are shown in violet. (B) Effects on pancreatic endocrine functions. Both GIP and GLP-1 have insulinotropic effects on pancreatic β-cells during hyperglycemia. GIP has a glucagonotropic effect in pancreatic α-cells during hypoglycemia but no effect during hyperglycemia. GLP-1 has an indirect glucagonostatic effect during hyperglycemia but no effect during hypoglycemia. (C) Effects in the brain. Both GIP and GLP-1 activate their respective receptors in distinct neurons within central nervous system (e.g., hypothalamus) to increase the sense of satiety. Notably, GLP-1, but not GIP, is directly produced in the brain (e.g., nucleus of the solitary tract (NST) and hypothalamus), but both hormones can cross blood-brain barrier from systemic circulation. The central nervous system [e.g., rostral ventrolateral medulla (RVLM)] transmits GLP-1 signaling to increase sympathetic tone, which in turn enhances lipolysis in adipose tissue. The central nervous system (e.g., NST) also relays GLP-1 signaling between afferent and efferent vagal nerves to delay gastric emptying. (D) Effects on the stomach. GLP-1delays the gastric emptying, thereby reducing the postprandial lipid and carbohydrate surges. This effect of GLP-1 is at least partially mediated by the neuronal pathway, including afferent vagal nerve, brainstem (e.g., NST), and efferent vagal nerve. GIP does not have a similar mechanism for regulating gastric emptying. (E) Effects on adipose tissue and liver. GIP binds GIPR in adipose tissue and activates a signaling cascade that increases lipoprotein lipase (LPL) expression and secretion. LPL enhances triglyceride (TG) clearance from circulation, facilitates the transport of TG to adipocytes for lipogenesis, and attenuates ectopic fat accumulation in visceral organs. GLP-1 indirectly enhances lipolysis via increased sympathetic activity through the central nervous system. Both GIP and GLP-1 have indirect effects on the liver by increasing the secretion of adiponectin from adipose tissue and attenuating hypertriglyceridemia. These mechanisms reduce hepatic fat accumulation, ameliorate insulin resistance, and inhibits hepatic glucogenesis.
Figure 1 Physiological and Pharmacological Effects of GIP, GLP-1 and Their Receptor Agonists. (A) GIP and GLP-1 secretion. Enteroendocrine K cells in the upper gastrointestinal tract (duodenum and jejunum) and L cells in the distal gut (ileum and colon) produce and secret GIP and GLP-1, respectively, into the circulation. GIP peptide and the downstream signaling pathways are depicted in blue, while GLP-1 peptide and the downstream signaling pathways are represented in red. The signaling pathways regulated by both GIP and GLP-1 are shown in violet. (B) Effects on pancreatic endocrine functions. Both GIP and GLP-1 have insulinotropic effects on pancreatic β-cells during hyperglycemia. GIP has a glucagonotropic effect in pancreatic α-cells during hypoglycemia but no effect during hyperglycemia. GLP-1 has an indirect glucagonostatic effect during hyperglycemia but no effect during hypoglycemia. (C) Effects in the brain. Both GIP and GLP-1 activate their respective receptors in distinct neurons within central nervous system (e.g., hypothalamus) to increase the sense of satiety. Notably, GLP-1, but not GIP, is directly produced in the brain (e.g., nucleus of the solitary tract (NST) and hypothalamus), but both hormones can cross blood-brain barrier from systemic circulation. The central nervous system [e.g., rostral ventrolateral medulla (RVLM)] transmits GLP-1 signaling to increase sympathetic tone, which in turn enhances lipolysis in adipose tissue. The central nervous system (e.g., NST) also relays GLP-1 signaling between afferent and efferent vagal nerves to delay gastric emptying. (D) Effects on the stomach. GLP-1delays the gastric emptying, thereby reducing the postprandial lipid and carbohydrate surges. This effect of GLP-1 is at least partially mediated by the neuronal pathway, including afferent vagal nerve, brainstem (e.g., NST), and efferent vagal nerve. GIP does not have a similar mechanism for regulating gastric emptying. (E) Effects on adipose tissue and liver. GIP binds GIPR in adipose tissue and activates a signaling cascade that increases lipoprotein lipase (LPL) expression and secretion. LPL enhances triglyceride (TG) clearance from circulation, facilitates the transport of TG to adipocytes for lipogenesis, and attenuates ectopic fat accumulation in visceral organs. GLP-1 indirectly enhances lipolysis via increased sympathetic activity through the central nervous system. Both GIP and GLP-1 have indirect effects on the liver by increasing the secretion of adiponectin from adipose tissue and attenuating hypertriglyceridemia. These mechanisms reduce hepatic fat accumulation, ameliorate insulin resistance, and inhibits hepatic glucogenesis.CC BY · PubMed Central
Figure 2 Amino Acid Sequences of Exendin-4, GLP-1, GIP, and Their Derivatives. Exendin-4 and its derivatives are depicted in green, while GLP-1 and its derivatives are represented in red. GLP-1 is conserved across mammalian species. Human GIP and some mammalian (porcine and bovine) GIP variants are shown in blue. The amino acids of the derivatives that differ from their backbone sequences are highlighted in black and underlined. The amino acids of bovine and porcine GIP that are not homologous to human GIP, as well as the amino acids of Heloderma Suspectum GLP-1 that are not homologous to human GLP-1, are also underlined. In NNC0090-2746 and tirzepatide, amino acids shared by both GIP and GLP-1 are displayed in violet, those unique to GIP are shown in blue, those exclusive to GLP-1 are shown in red, and those specific to exendin-4 are displayed in green, while those not identical to GIP, GLP-1 or exendin-4 are depicted in black and underlined. The acylated lysine residues in liraglutide, semaglutide, NNC0090-2746, and tirzepatide are indicated by yellow-filled circles. Seven amino acids conserved in all peptides are highlighted in the boxes.
Figure 2 Amino Acid Sequences of Exendin-4, GLP-1, GIP, and Their Derivatives. Exendin-4 and its derivatives are depicted in green, while GLP-1 and its derivatives are represented in red. GLP-1 is conserved across mammalian species. Human GIP and some mammalian (porcine and bovine) GIP variants are shown in blue. The amino acids of the derivatives that differ from their backbone sequences are highlighted in black and underlined. The amino acids of bovine and porcine GIP that are not homologous to human GIP, as well as the amino acids of Heloderma Suspectum GLP-1 that are not homologous to human GLP-1, are also underlined. In NNC0090-2746 and tirzepatide, amino acids shared by both GIP and GLP-1 are displayed in violet, those unique to GIP are shown in blue, those exclusive to GLP-1 are shown in red, and those specific to exendin-4 are displayed in green, while those not identical to GIP, GLP-1 or exendin-4 are depicted in black and underlined. The acylated lysine residues in liraglutide, semaglutide, NNC0090-2746, and tirzepatide are indicated by yellow-filled circles. Seven amino acids conserved in all peptides are highlighted in the boxes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 275 references

Research works printed but not linked: 1

  1. 2020, Rybelsus prescribing information

Cited by

See all 341

Metadata

Authors
Liu, Q. K.
Affiliations
Montgomery General Hospital (US)
Corresponding author
Liu, Qiyuan Keith
Venue
Frontiers in Endocrinology
Published
2024-07-24
Volume
15
Pages
1431292-1431292
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4400956092
Cited by
265
References
279
Citations by year
2026: 156 · 2025: 107 · 2024: 2
FWCI
15.55
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, GIP/GLP-1 receptor agonist, incretin mimetics, type 2 diabetes, obesity, insulin secretion, satiety, lipogenesis, lipolysis, adiponectin, cardiovascular disease prevention, weight management, dyslipidemia, metabolic homeostasis
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. https://app.cochat.ai/papers/10.3389/fendo.2024.1431292
The paper
Liu, Q. K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1431292

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.